Entering text into the input field will update the search result below

3 Things In Biotech, March 4, 2018: Biogen Forfeits, Regeneron Advances, Jazz Isn't Tired Yet

Mar. 05, 2018 8:00 AM ETABBV, BIIB, JAZZ, REGN, SNY6 Comments
Zach Hartman profile picture
Zach Hartman


  • Biogen and AbbVie throw in the towel with daclizumab.
  • Regeneron gets review to expand its anti-inflammatory drug.
  • Jazz Pharmaceuticals seeks its day for a sleep drug.

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Biogen and AbbVie throw in the towel with daclizumab

Company: Biogen (BIIB) and AbbVie (ABBV)

Therapy: Daclizumab

Disease: Relapsing multiple sclerosis

News: BIIB and ABBV announced that they would jointly withdraw their CD25 monoclonal antibody daclizumab from the worldwide market due to concerns about the adverse event profile, which has proven too complex and dangerous to justify the risk of treatment.

Looking forward: Thus ends a saga where BIIB and ABBV were unable to make this agent stick due to safety concerns, as uptake was too slow to compete with other blockbusters in the multiple sclerosis space. As such, it comes as little surprise that the companies have opted to pull the plug. Of course, this is a sad case study on the challenges that can befall a seemingly effective drug even after it's approved.

Likely, this news won't put much of a dent into these large companies, and cutting the weight anchoring their continued growth is important for focusing their priorities.

Regeneron gets review to expand its anti-inflammatory drug

Company: Regeneron (REGN) and Sanofi (SNY)

Therapy: Dupilumab

Disease: Moderate-to-severe asthma

News: REGN and SNY announced that their supplemental new drug application has been accepted for dupilumab. This application seeks to expand the marketed indication from atopic dermatitis that is not well controlled to the use as maintenance therapy for adults and adolescents with moderate-to-severe asthma. The companies guide an expected action date from the FDA of October 20, 2018.

Looking forward: Dupilumab was approved for the first time only last year, so it is not clear yet

This article was written by

Zach Hartman profile picture
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)


Do you feel JAZZ’ current product for narcolepsy which I believe is their biggest money maker & which needs to be taken 2x a night may be in for some trouble in 2019 if the Avadel phase 3 Rest-On trial for sodium oxybate micro pump gains approval
Zach Hartman profile picture
It's possible, although I am not an expert in the space, by any stretch!
sfpdf profile picture

Doesn't JAZZ already have another product or two on the market for similar indications? If so, would this be more efficacious? Fewer side effects? Thanks.
Zach Hartman profile picture
Hi sfpdf,

I am afraid I am not intimately familiar with those other products, so I can't in good conscience try to make a useful comment on them!
danwatson888 profile picture
Zach thanks for the updates - I will be buying (ABBV) $ABBV on any dips - This is great company right now - http://bit.ly/2FUTYLL
Zach Hartman profile picture
Lots of big stuff in the oncology pipeline, for sure!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

Related Stocks

SymbolLast Price% Chg
AbbVie Inc.
Biogen Inc.
Jazz Pharmaceuticals plc
Regeneron Pharmaceuticals, Inc.

Related Analysis

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.